Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Jul;22(1):32–35. doi: 10.1128/aac.22.1.32

Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults.

A S Lea, A W Sudan, B A Wood, L O Gentry
PMCID: PMC183669  PMID: 6214996

Abstract

Eighty-nine patients with clinical and laboratory evidence of acute urinary tract infection were randomized to therapy with either moxalactam (500 mg) or cefazolin (1 g) every 12 h. Escherichia coli was the predominant pathogen in both groups (92.6 versus 90.2%). Therapy was continued for 3 days after the patient defervesced. The minimum hospital stay was 5 days. Sequential urine cultures were obtained on day 3, at discharge, and 5 to 10 days after the cessation of therapy. THe average duration of hospital stay was 5.6 days for both groups of patients. THe incidence of recurrent infection was similar in uncomplicated patients (9.1 versus 10%) and in complicated patients with a condition predisposing them to urinary tract infections (43 versus 42%). Moxalactam-treated patients had a higher incidence of reversible hepatic enzyme elevation (36%) and Streptococcus faecalis superinfections (12.2%). Moxalactam is as effective as cefazolin for the elimination of gram-negative pathogens from the urine of patients with acute urinary tract infections, but it is associated with a higher incidence of reversible side effects.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Thornsberry C., Jones R. N., Gerlach E. H. Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935). Antimicrob Agents Chemother. 1980 Nov;18(5):716–721. doi: 10.1128/aac.18.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fass R. J. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Oct;16(4):503–509. doi: 10.1128/aac.16.4.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Flournoy D. J., Perryman F. A. LY127935, a new beta-lactam antibiotic, versus Proteus, Klebsiella, Serratia, and Pseudomonas. Antimicrob Agents Chemother. 1979 Nov;16(5):641–643. doi: 10.1128/aac.16.5.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hall W. H., Opfer B. J., Gerding D. N. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli. Antimicrob Agents Chemother. 1980 Feb;17(2):273–279. doi: 10.1128/aac.17.2.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jones R. N., Fuchs P. C., Sommers H. M., Gavan T. L., Barry A. L., Gerlach E. H. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin. Antimicrob Agents Chemother. 1980 Apr;17(4):750–756. doi: 10.1128/aac.17.4.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jorgensen J. H., Crawford S. A., Alexander G. A. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1980 Jun;17(6):937–942. doi: 10.1128/aac.17.6.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Neu H. C., Aswapokee N., Fu K. P., Aswapokee P. Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother. 1979 Aug;16(2):141–149. doi: 10.1128/aac.16.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Parsons J. N., Romano J. M., Levison M. E. Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother. 1980 Feb;17(2):226–228. doi: 10.1128/aac.17.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Reimer L. G., Mirrett S., Reller L. B. Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates. Antimicrob Agents Chemother. 1980 Mar;17(3):412–416. doi: 10.1128/aac.17.3.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Scheld W. M., Spyker D. A., Donowitz G. R., Bolton W. K., Sande M. A. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother. 1981 Apr;19(4):613–619. doi: 10.1128/aac.19.4.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Srinivasan S., Fu K. P., Neu H. C. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. Antimicrob Agents Chemother. 1981 Feb;19(2):302–305. doi: 10.1128/aac.19.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tofte R. W., Rotschafer J., Solliday J., Crossley K. B. Moxalactam therapy for a wide spectrum of bacterial infections in adults. Antimicrob Agents Chemother. 1981 May;19(5):740–744. doi: 10.1128/aac.19.5.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Trager G. M., White G. W., Zimelis V. M., Panwalker A. P. LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity. Antimicrob Agents Chemother. 1979 Sep;16(3):297–300. doi: 10.1128/aac.16.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Weaver S. S., LeBlanc B. M., Bodey G. P. In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic. Antimicrob Agents Chemother. 1980 Jan;17(1):92–95. doi: 10.1128/aac.17.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wise R., Andrews J. M., Bedford K. A. LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother. 1979 Sep;16(3):341–345. doi: 10.1128/aac.16.3.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Yoshida T., Matsuura S., Mayama M., Kameda Y., Kuwahara S. Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation. Antimicrob Agents Chemother. 1980 Mar;17(3):302–312. doi: 10.1128/aac.17.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Yu V. L. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med. 1981 Jun;94(6):784–785. doi: 10.7326/0003-4819-94-6-784. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES